On 1 October FDA recorded a supplement to an abbreviated new drug application (ANDA) for generic olanzapine held by Sandoz. A supplement to a generic application usually covers manufacturing, labelling alignment with the reference product, or similar administrative changes. The FDA entry does not describe a new indication, a dosing change or a safety signal.
For prescribers this changes nothing about how olanzapine is used. It is a reminder that olanzapine remains among the antipsychotics with the heaviest metabolic burden, and that the monitoring obligations described in today's pearl apply whichever manufacturer supplies it.
- No new indication, dose or safety warning is associated with this supplement.
- Generic olanzapine products are interchangeable in use; monitoring is unchanged.
- Keep weight, glucose and lipid monitoring in place for anyone taking olanzapine.
- In India, olanzapine is widely available as a generic; this US filing does not affect CDSCO status.
Why it matters
Most FDA entries for generic antipsychotics are administrative, and reading them as safety news would be a mistake.
Don't overread it
A licence supplement is not a safety finding or a new indication.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for psychiatry, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free